Tricyclic antidepressants and the risk of reflux esophagitis

American Journal of Gastroenterology

Volumn 102, Issue 9, 2007, Pages 1870-1877

  Van Soest, Eva M ^a   Dieleman, Jeanne P ^a   Siersema, Peter D ^a   Schoof, Leny ^a   Sturkenboom, Miriam C J M ^a   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BENZODIAZEPIN 2 ONE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; GLYCERYL TRINITRATE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; XANTHENE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEPRESSION; DOSE RESPONSE; ENDOSCOPY; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROPATHIC PAIN; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SEX RATIO;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CASE-CONTROL STUDIES; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGITIS, PEPTIC; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 34548139333     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01320.x     Document Type: Article

References (25)

1. Moayyedi P, Axon ATR. Review article: Gastro-oesophageal reflux disease - the extent of the problem. Aliment Phamacol Ther 2005 22 (Suppl 1 11 9.
2. Quigley EMM, Hungin APS. Review article: Quality-of-life issues in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005 22 (Suppl 1 41 7.
3. Castell DO, Murray JA, Tutuian R, et al. Review article: The pathophysiology of gastro-oesphageal reflux disease - oesophageal manifestations. Aliment Pharmacol Ther 2004 20 (Suppl 9 14 25.
4. Lidums I, Checklin H, Mittal RK, et al. Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gut 1998 43 : 12 6.
5. Mittal RK, Holloway R, Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology 1995 109 : 1547 54.
6. Rashid MU, Bateman DN. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers. Br J Clin Pharmacol 1990 30 : 25 34.
7. Phaosawasdi K, Malmud LS, Tolin RD, et al. Cholinergic effect on esophageal transit and clearance. Gastroenterology 1981 81 : 915 20.
8. Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: A community study. Aliment Pharmacol Ther 2005 21 : 821 7.
9. Zimmerman J. Irritable bowel, smoking and oesophageal acid exposure: An insight into the nature of symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2004 20 : 1297 303.
10. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 340 : 825 31.
11. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinoma in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998 7 : 749 56.
12. Bevolking per regio naar leeftijd, geslacht en burgerlijke staat. Voorburg, The Netherlands : Centraal Bureau voor Statistiek, 2006.
13. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: The effect of fifteen years of evolution. Fam Pract 1992 9 : 330 9.
14. Anonymous. ATC and DDD values. Geneva : World Health Organization, 1996.
15. Vlug AE, vander Lei J, Mossereld BMT, et al. Postmarketing surveillance based on electronic patient records: The IPCI project. Methods Inf Med 1999 38 : 339 44.
16. Von Korff M, Wagner EH, Saunders K. A Chronic Disease Score from automated pharmacy data. J Clin Epidemiol 1992 45 : 197 203.
17. Castell DO. The lower esophageal sphincter. Physiologic and clinical aspects. Ann Intern Med 1975 83 : 390 401.
18. Dent J, Dodds WI, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980 65 : 256 67.
19. Mittal RK, McCallum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 1988 95 : 593 9.
20. Dent J, Holloway RH, Toouli J, et al. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 1988 29 : 1020 8.
21. Vaezi MF, Richter JE. Role of acid and duodenogastro-esophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996 111 : 1192 9.
22. College van Zorgverzekeringen. Farmacotherapeutisch Kompas: Central Nervous System/Depression and anti-depressants, Table 1. Available at : http://www.fk.cvz.nl/. Accessed September 9, 2006.
23. Lee YC, Wang HP, Chiu HM, et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: A prospective study based on screening endoscopy. J Gastroenterol Hepatol 2006 21 : 798 804.
24. Bradley LA, Richter JE, Pulliam TJ, et al. The relationship between stress and symptoms of gastroesophageal reflux: The influence of psychological factors. Am J Gastroenterol 1993 88 : 11 9.
25. Kikendall JW. Pill esophagitis. J Clin Gastroenterol 1999 28 : 298 305.